
Go or no go? Lilly’s valuable diabetes contender
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.

Takeover-driven resurgence fails to materialise for biotech
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.

Go or no go? Bristol's first-in-class hopes
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.

Argenx takes a step towards convenience
The group is taking a subcutaneous formulation of efgartigimod to regulators, but is keeping quiet about price.

Go or no go? Bristol’s Lag3 debut
March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.